PDUFA Negotiations End With Differences To Resolve In Commitment Letter
This article was originally published in The Tan Sheet
The entire PDUFDA VI reauthorization process likely is more than a year from completion, but agreeing on a draft commitment letter is a major milestone for FDA and the pharma industry. It will serve as the foundation of the legislative phase expected to begin in early 2017.
You may also be interested in...
In interview with the Pink Sheet, Center for Drug Evaluation and Research director discusses her 30-year career, retirement speculation, and upcoming projects.
User fee revenue expected to break $1bn threshold by FY 2020, but growth looks to be slower than last few years.
FDA and industry also talking about improvements to combination product review process as part of user fee program renewal.